Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Syndax Pharmaceuticals Q2 EPS $(0.62) Down From $(0.44) YoY

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share. This is a 40.91 percent decrease over losses of $(0.44) per share from the same period last year.
byBenzinga Newsdesk
August 8, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share. This is a 40.91 percent decrease over losses of $(0.44) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Pharvaris’ Promising Oral Treatment Solutions For Treating Swollen Blood Vessels – Analyst Sees 35% Upside

By Vandana Singh
September 25, 3:47 PM
Wedbush has initiated coverage on Pharvaris N.V. (NASDAQ: PHVS), noting that the company stands out as one of the players with their strategy to develop and advance oral therapeutic options in both the acute and prophylactic settings for hereditary angioedema (HAE).

PHVS